Epigenetics of prostate cancer and the prospect of identification of novel drug targets by RNAi screening of epigenetic enzymes

Mari Björkman (Corresponding Author), Juha K. Rantala, Matthias Nees, Olli Kallioniemi

Research output: Contribution to journalArticleScientificpeer-review

4 Citations (Scopus)


Alterations in epigenetic processes probably underlie most human malignancies. Novel genome-wide techniques, such as chromatin immunoprecipitation and high-throughput sequencing, have become state-of-the-art methods to map the epigenomic landscape of development and disease, such as in cancers. Despite these advances, the functional significance of epigenetic enzymes in cancer progression, such as prostate cancer, remain incompletely understood. A comprehensive mapping and functional understanding of the cancer epigenome will hopefully help to facilitate development of novel cancer therapy targets and improve future diagnostics. The authors have developed a novel cell microarray-based high-content siRNA screening technique suitable to address the putative functional role and impact of all known putative and novel epigenetic enzymes in cancer, including prostate cancer.
Original languageEnglish
Pages (from-to)683-689
Issue number5
Publication statusPublished - 2010
MoE publication typeA1 Journal article-refereed



  • cell microarray technology
  • epigenetics
  • high-throughput screening
  • HTS
  • PrCa
  • prostate cancer
  • siRNA

Cite this